BioLife Solutions (NASDAQ:BLFS) Issues Earnings Results

BioLife Solutions (NASDAQ:BLFS) issued its quarterly earnings data on Monday. The medical equipment provider reported $0.26 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.32, RTT News reports. BioLife Solutions had a negative net margin of 38.98% and a negative return on equity of 6.61%. The business had revenue of $22.71 million for the quarter, compared to the consensus estimate of $21.73 million. During the same period in the previous year, the firm earned ($0.21) EPS. BioLife Solutions updated its FY 2025 guidance to EPS.

BioLife Solutions Price Performance

NASDAQ BLFS opened at $24.51 on Tuesday. BioLife Solutions has a 52 week low of $14.84 and a 52 week high of $29.55. The firm has a market capitalization of $1.14 billion, a P/E ratio of -23.12 and a beta of 1.91. The company has a quick ratio of 1.78, a current ratio of 2.78 and a debt-to-equity ratio of 0.03. The company has a 50-day moving average price of $26.74 and a 200-day moving average price of $25.50.

Wall Street Analyst Weigh In

A number of analysts have recently commented on BLFS shares. HC Wainwright dropped their target price on shares of BioLife Solutions from $29.00 to $27.00 and set a “buy” rating on the stock in a report on Monday, November 18th. TD Cowen upped their price target on shares of BioLife Solutions from $28.00 to $31.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. KeyCorp upped their price target on shares of BioLife Solutions from $30.00 to $33.00 and gave the stock an “overweight” rating in a research note on Friday, December 13th. Benchmark reiterated a “buy” rating and issued a $30.00 price target on shares of BioLife Solutions in a research note on Thursday, December 19th. Finally, Craig Hallum upped their price target on shares of BioLife Solutions from $30.00 to $32.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. One analyst has rated the stock with a sell rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $29.43.

Insider Activity

In other news, EVP Aby J. Mathew sold 7,604 shares of the company’s stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $27.33, for a total transaction of $207,817.32. Following the completion of the sale, the executive vice president now owns 276,315 shares of the company’s stock, valued at $7,551,688.95. This represents a 2.68 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Troy Wichterman sold 987 shares of the company’s stock in a transaction dated Monday, January 6th. The shares were sold at an average price of $27.02, for a total transaction of $26,668.74. Following the sale, the chief financial officer now directly owns 121,779 shares of the company’s stock, valued at $3,290,468.58. The trade was a 0.80 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 10,009 shares of company stock valued at $272,594 in the last quarter. 2.20% of the stock is currently owned by insiders.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.